Cranial radiotherapy has minimal benefit in children with central nervous system involvement in T-ALL-Reference-Cited by-同舟云学术

Cranial radiotherapy has minimal benefit in children with central nervous system involvement in T-ALL

Published:2023-11-30 Issue:23 Volume:7 Page:7231-7234
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

O’Connor David¹²^ORCID,Joy Melvin³^ORCID,Enshaei Amir³,Kirkwood Amy⁴,Kearns Pamela R.⁵^ORCID,Samarasinghe Sujith²,Moppett John⁶^ORCID,Moorman Anthony V.³^ORCID,Vora Ajay²

Affiliation:

1. 1UCL Cancer Institute, University College London, London, United Kingdom

2. 2Department of Haematology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom

3. 3Wolfson Childhood Cancer Centre, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom

4. 4Cancer Research UK & University College London Cancer Trials Centre, UCL Cancer Institute, University College London, London, United Kingdom

5. 5Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, United Kingdom

6. 6Department of Paediatric Oncology, Bristol Royal Hospital for Children, Bristol, United Kingdom

Publisher

American Society of Hematology

Subject

Hematology

Link

https://ashpublications.org/bloodadvances/article-pdf/7/23/7231/2176333/blooda_adv-2023-011267-main.pdf

Reference20 articles.

1. How I treat newly diagnosed T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma in children;Teachey;Blood,2020

2. Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia;Teachey;Lancet Oncol,2019

3. Treating childhood acute lymphoblastic leukemia without cranial irradiation;Pui;N Engl J Med,2009

4. Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial;Vora;Lancet Oncol,2013

5. Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial;Vora;Lancet Oncol,2014